SNDX
NASDAQ · Biotechnology
Syndax Pharmaceuticals Inc
$24.23
+0.23 (+0.96%)
Financial Highlights (FY 2026)
Revenue
176.96M
Net Income
-293,056,550
Gross Margin
96.0%
Profit Margin
-165.6%
Rev Growth
—
D/E Ratio
5.32
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 96.0% | 96.5% | 49.4% | 49.4% |
| Operating Margin | -158.4% | -1,291.0% | -25.0% | -26.7% |
| Profit Margin | -165.6% | -1,278.8% | -29.1% | -22.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 176.96M | 42.66M | 332.47M | 314.66M |
| Gross Profit | 169.81M | 41.17M | 164.17M | 155.38M |
| Operating Income | -280,393,028 | -550,683,357 | -83,095,579 | -83,885,898 |
| Net Income | -293,056,550 | -516,701,989 | -96,723,913 | -70,006,891 |
| Gross Margin | 96.0% | 96.5% | 49.4% | 49.4% |
| Operating Margin | -158.4% | -1,291.0% | -25.0% | -26.7% |
| Profit Margin | -165.6% | -1,278.8% | -29.1% | -22.3% |
| Rev Growth | — | -44.7% | -3.0% | +7.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 801.13M | 487.70M | 451.31M | 465.02M |
| Total Equity | 150.55M | 408.83M | 843.32M | 828.46M |
| D/E Ratio | 5.32 | 1.19 | 0.54 | 0.56 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -281,698,597 | -581,608,963 | -125,567,751 | -117,470,983 |
| Free Cash Flow | — | — | -63,645,585 | -69,021,041 |